Gen-Probe Receives Canadian Regulatory Approval for Progensa

Gen-Probe announced to-day that Health Canada has granted the Company a medical device license for the PROGENSA(R) PCA3 assay, a new molecular urine test that helps determine the need for repeat biopsies in men suspected of having prostate cancer. Gen-Probe acquired exclusive worldwide diagnostic rights to the PCA3 gene from DiagnoCure

in November of 2003. "Receiving a Canadian regulatory license for the PROGENSA PCA3 assay is another important milestone in our efforts to help physicians and their patients make better, more informed decisions about whether to conduct repeat prostate biopsies in men at risk of having cancer," said Carl Hull, Gen-Probe's president and chief executive officer.